A Multicenter Randomized Phase II Trial in NSCLC [non-small cell lung cancer] Stage IV and IIIB (T4 With Pleural Effusion) in Elderly Independent Patients the Schedule Docetaxel / Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by/ Gemcitabine When Progression
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Erlotinib (Primary) ; Docetaxel; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Oct 2013 Biomarkers information updated
- 20 Sep 2011 Primary endpoint 'Time-to-disease-progression' has not been met.
- 20 Sep 2011 Status changed from discontinued to completed as reported in the British Journal of Cancer.